

# PF 43(3) Table of Contents

## Publish date: April 28, 2017

---

### PROPOSED IRA

- [Proposed Interim Revision Announcements](#)

### IN-PROCESS REVISION

- [In-Process Revision](#)

### GENERAL CHAPTERS

- [<381> ELASTOMERIC CLOSURES FOR INJECTIONS \(USP41-NF36 1S\)](#)
- [<382> ELASTOMERIC CLOSURE FUNCTIONALITY IN INJECTABLE PHARMACEUTICAL PACKAGING/DELIVERY SYSTEMS \[NEW\] \(USP41-NF36 1S\)](#)
- [<660> CONTAINERS—GLASS \(USP41-NF36 1S\)](#)
- [<665> POLYMERIC COMPONENTS AND SYSTEMS USED IN THE MANUFACTURING OF PHARMACEUTICAL AND BIOPHARMACEUTICAL DRUG PRODUCTS \[NEW\] \(USP41-NF36 1S\)](#)
- [<1168> COMPOUNDING FOR PHASE I INVESTIGATIONAL STUDIES \[NEW\] \(USP41-NF36 1S\)](#)
- [<1381> ELASTOMERIC EVALUATION OF ELASTOMERIC COMPONENTS USED IN PHARMACEUTICAL PACKAGING/DELIVERY SYSTEMS \[NEW\] \(USP41-NF36 1S\)](#)
- [<1382> ASSESSMENT OF ELASTOMERIC CLOSURE FUNCTIONALITY IN INJECTABLE PHARMACEUTICAL PACKAGING/DELIVERY SYSTEMS \[NEW\] \(USP41-NF36 1S\)](#)
- [<1660> EVALUATION OF THE INNER SURFACE DURABILITY OF GLASS CONTAINERS \(USP41-NF36 1S\)](#)
- [<1665> PLASTIC COMPONENTS AND SYSTEMS USED TO MANUFACTURE PHARMACEUTICAL DRUG PRODUCTS \[NEW\] \(USP41-NF36 1S\)](#)
- [<2040> DISINTEGRATION AND DISSOLUTION OF DIETARY SUPPLEMENTS \(USP41-NF36 1S\)](#)

### REAGENTS, INDICATORS, AND SOLUTIONS

#### Reagent Specifications

- [Ammonium Hydrogen Difluoride \[NEW\] \(USP41-NF36 1S\)](#)
- [Blood Group A1 Red Blood Cells and Blood Group B Red Blood Cells \(USP41-NF36 1S\)](#)
- [Chloromethylnitroimidazole \[NEW\] \(USP41-NF36 1S\)](#)
- [Dimethylcarbonate \[NEW\] \(USP41-NF36 1S\)](#)
- [Dimidium Bromide \[NEW\] \(USP41-NF36 1S\)](#)
- [Fluoroandrostadiene Carboxylic Acid \[NEW\] \(USP41-NF36 1S\)](#)
- [Gadolinium Sulfate \(USP41-NF36 1S\)](#)
- [Lithium Sulfate \(USP41-NF36 1S\)](#)
- [Petroleum Ether \[NEW\] \(USP41-NF36 1S\)](#)
- [Sulfan Blue \[NEW\] \(USP41-NF36 1S\)](#)
- [n-Tricosane \(USP41-NF36 1S\)](#)
- [Water, Ammonia-Free \(USP41-NF36 1S\)](#)

#### Test Solutions

- 0.1 N Sodium Chloride TS [NEW] (USP41-NF36 1S)
- 10 N Sulfuric Acid TS [NEW] (USP41-NF36 1S)

#### **Volumetric Solutions**

- 0.01 M Sodium Thiosulfate VS (USP41-NF36 1S)

#### **Chromatographic Columns**

- L86 (USP41-NF36 1S)
- L112 [NEW] (USP41-NF36 1S)

#### **REFERENCE TABLES**

##### **Container Specifications**

- Container Specifications [NEW] (USP41-NF36 1S)

##### **Description and Solubility**

- Description and Relative Solubility of USP and NF Articles [NEW] (USP41-NF36 1S)
- Description and Solubility - B
- Description and Solubility - D
- Description and Solubility - E
- Description and Solubility - M

#### **USP MONOGRAPHS**

- Acetaminophen Tablets (USP41-NF36 1S)
- Amitriptyline Hydrochloride (USP41-NF36 1S)
- Amitriptyline Hydrochloride Injection (USP41-NF36 1S)
- Amitriptyline Hydrochloride Tablets (USP41-NF36 1S)
- Amoxicillin (USP41-NF36 1S)
- Anthrax Vaccine Adsorbed (USP41-NF36 1S)
- Azathioprine Tablets (USP41-NF36 1S)
- Azelastine Hydrochloride Ophthalmic Solution [NEW] (USP41-NF36 1S)
- Azithromycin (USP41-NF36 1S)
- Azithromycin Tablets (USP41-NF36 1S)
- Benzphetamine Hydrochloride [NEW] (USP41-NF36 1S)
- Benzphetamine Hydrochloride Tablets [NEW] (USP41-NF36 1S)
- Carbidopa and Levodopa Extended-Release Tablets (USP41-NF36 1S)
- Carprofen (USP41-NF36 1S)
- Celecoxib Capsules [NEW] (USP41-NF36 1S)
- Deferasirox [NEW] (USP41-NF36 1S)
- Desmopressin Acetate (USP41-NF36 1S)
- Dexamethasone Ophthalmic Suspension (USP41-NF36 1S)
- Dexamethasone Sodium Phosphate Injection (USP41-NF36 1S)
- Dihydrocodeine Bitartrate (USP41-NF36 1S)
- Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution (USP41-NF36 1S)
- Eletriptan Hydrobromide [NEW] (USP41-NF36 1S)
- Epinephrine Injection (USP41-NF36 1S)
- Estradiol Benzoate (USP41-NF36 1S)

- Estriol (USP41-NF36 1S)
- Ethotoin (USP41-NF36 1S)
- Ethotoin Tablets (USP41-NF36 1S)
- Fludeoxyglucose F 18 Injection (USP41-NF36 1S)
- Gentamicin Sulfate (USP41-NF36 1S)
- Hydroxyzine Pamoate Oral Suspension (USP41-NF36 1S)
- Imipenem (USP41-NF36 1S)
- Lactulose [NEW] (USP41-NF36 1S)
- Lidocaine (USP41-NF36 1S)
- Lidocaine Hydrochloride (USP41-NF36 1S)
- Lidocaine Hydrochloride Oral Topical Solution (USP41-NF36 1S)
- Lidocaine Hydrochloride Topical Solution (USP41-NF36 1S)
- Liothyronine Sodium (USP41-NF36 1S)
- Maprotiline Hydrochloride (USP41-NF36 1S)
- Mebendazole Tablets (USP41-NF36 1S)
- Metaproterenol Sulfate Inhalation Aerosol (USP41-NF36 1S)
- Methotrexate (USP41-NF36 1S)
- Milnacipran Hydrochloride [NEW] (USP41-NF36 1S)
- Milnacipran Hydrochloride Tablets [NEW] (USP41-NF36 1S)
- Ammonia N 13 Injection (USP41-NF36 1S)
- Octinoxate (USP41-NF36 1S)
- Octisalate (USP41-NF36 1S)
- Octocrylene (USP41-NF36 1S)
- Omega-3-Acid Ethyl Esters Capsules (USP41-NF36 1S)
- Phentolamine Mesylate (USP41-NF36 1S)
- Pilocarpine Hydrochloride Tablets (USP41-NF36 1S)
- Pravastatin Sodium (USP41-NF36 1S)
- Promethazine and Phenylephrine Hydrochloride Oral Solution (USP41-NF36 1S)
- Rizatriptan Benzoate Orally Disintegrating Tablets (USP41-NF36 1S)
- Selenium Sulfide Topical Suspension (USP41-NF36 1S)
- Somatropin (USP41-NF36 1S)
- Sumatriptan Nasal Spray (USP41-NF36 1S)
- Tacrolimus Ointment [NEW] (USP41-NF36 1S)
- Taurine (USP41-NF36 1S)
- Terbutaline Sulfate Inhalation Aerosol (USP41-NF36 1S)
- Testosterone Enanthate (USP41-NF36 1S)
- Testosterone Enanthate Injection (USP41-NF36 1S)
- Tetracycline (USP41-NF36 1S)
- Tetracycline Hydrochloride (USP41-NF36 1S)
- Tetrahydrozoline Hydrochloride Ophthalmic Solution (USP41-NF36 1S)
- Tiamulin (USP41-NF36 1S)
- Tiamulin Fumarate (USP41-NF36 1S)
- Trandolapril (USP41-NF36 1S)
- Trazodone Hydrochloride Tablets (USP41-NF36 1S)
- Triptorelin Pamoate [NEW] (USP41-NF36 1S)
- Verapamil Hydrochloride Injection (USP41-NF36 1S)
- Xylazine (USP41-NF36 1S)

#### DIETARY SUPPLEMENT MONOGRAPHS

- Ascorbic Acid Chewable Gels [NEW] (USP41-NF36 1S)
- Cholecalciferol Chewable Gels [NEW] (USP41-NF36 1S)
- Menaquinone-4 [NEW] (USP41-NF36 1S)

- [Methylcobalamin \(USP41-NF36 1S\)](#)
- [Methylcobalamin Tablets \(USP41-NF36 1S\)](#)

#### **NF MONOGRAPHS**

- [Squalane \(USP41-NF36 1S\)](#)

#### **STAGE 4 HARMONIZATION**

- [Stage 4 Harmonization](#)

#### **STIMULI TO THE REVISION PROCESS**

- [STIMULI TO THE REVISION PROCESS](#)
- [Applying the USP <905> Content Uniformity Zero Tolerance Criterion to Large Sample Sizes](#)
- [Drug Products Containing Nanomaterials](#)
- [PROPOSALS FOR DATA INTERPRETATION IN THE CONTEXT OF DETERMINATION OF AERODYNAMIC PARTICLE SIZE DISTRIBUTION PROFILE FOR ORALLY INHALED PRODUCTS](#)